Argyle Capital Management Inc. lowered its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 22.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,025 shares of the medical instruments supplier’s stock after selling 5,250 shares during the quarter. Argyle Capital Management Inc.’s holdings in OraSure Technologies were worth $406,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Federated Investors Inc. PA grew its position in OraSure Technologies by 505.6% during the 2nd quarter. Federated Investors Inc. PA now owns 312,595 shares of the medical instruments supplier’s stock worth $5,395,000 after acquiring an additional 260,977 shares during the last quarter. Parametric Portfolio Associates LLC raised its stake in shares of OraSure Technologies by 103.1% in the first quarter. Parametric Portfolio Associates LLC now owns 178,035 shares of the medical instruments supplier’s stock worth $2,302,000 after purchasing an additional 90,361 shares during the last quarter. Chicago Equity Partners LLC grew its holdings in shares of OraSure Technologies by 38.3% in the second quarter. Chicago Equity Partners LLC now owns 78,430 shares of the medical instruments supplier’s stock worth $1,354,000 after acquiring an additional 21,730 shares during the period. USA Financial Portformulas Corp grew its holdings in shares of OraSure Technologies by 31.0% in the second quarter. USA Financial Portformulas Corp now owns 56,653 shares of the medical instruments supplier’s stock worth $978,000 after acquiring an additional 13,421 shares during the period. Finally, TIAA CREF Investment Management LLC grew its holdings in shares of OraSure Technologies by 3.6% in the first quarter. TIAA CREF Investment Management LLC now owns 549,875 shares of the medical instruments supplier’s stock worth $7,110,000 after acquiring an additional 18,994 shares during the period. Hedge funds and other institutional investors own 92.93% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Argyle Capital Management Inc. Cuts Stake in OraSure Technologies, Inc. (NASDAQ:OSUR)” was first posted by Week Herald and is the property of of Week Herald. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://weekherald.com/2017/11/14/argyle-capital-management-inc-lowers-position-in-orasure-technologies-inc-osur.html.
Several analysts have issued reports on the company. Canaccord Genuity boosted their price target on OraSure Technologies from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, August 3rd. ValuEngine downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Jefferies Group LLC cut OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Zacks Investment Research raised OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 price objective on the stock in a research note on Wednesday, October 25th. Finally, BidaskClub cut OraSure Technologies from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 24th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $18.21.
OraSure Technologies, Inc. (OSUR) traded up $0.14 during mid-day trading on Tuesday, reaching $14.39. The company had a trading volume of 904,400 shares, compared to its average volume of 872,066. OraSure Technologies, Inc. has a 12 month low of $8.01 and a 12 month high of $23.01. The firm has a market cap of $864.24, a PE ratio of 27.40, a price-to-earnings-growth ratio of 2.74 and a beta of 1.39.
OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.09. The business had revenue of $42.30 million for the quarter, compared to analyst estimates of $40.87 million. OraSure Technologies had a net margin of 20.48% and a return on equity of 14.12%. The business’s revenue was up 31.0% on a year-over-year basis. During the same period last year, the company posted $0.11 EPS. equities research analysts expect that OraSure Technologies, Inc. will post 0.42 EPS for the current year.
In related news, insider Brian Smith sold 3,075 shares of the business’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $21.09, for a total transaction of $64,851.75. Following the completion of the transaction, the insider now owns 24,540 shares in the company, valued at $517,548.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Mara G. Aspinall bought 5,000 shares of the stock in a transaction that occurred on Tuesday, November 7th. The shares were purchased at an average price of $14.23 per share, with a total value of $71,150.00. Following the purchase, the director now owns 5,000 shares of the company’s stock, valued at approximately $71,150. The disclosure for this purchase can be found here. In the last three months, insiders sold 61,110 shares of company stock worth $1,362,463. 6.40% of the stock is owned by corporate insiders.
OraSure Technologies Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.